235 related articles for article (PubMed ID: 21933109)
1. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Podar K; Anderson KC
Curr Cancer Drug Targets; 2011 Nov; 11(9):1005-24. PubMed ID: 21933109
[TBL] [Abstract][Full Text] [Related]
2. [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Török S; Döme B
Magy Onkol; 2012 Mar; 56(1):3-15. PubMed ID: 22403757
[TBL] [Abstract][Full Text] [Related]
3. Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.
Wakelee HA; Schiller JH
Clin Lung Cancer; 2005 Sep; 7 Suppl 1():S31-8. PubMed ID: 16159417
[TBL] [Abstract][Full Text] [Related]
4. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
Kumar R; Crouthamel MC; Rominger DH; Gontarek RR; Tummino PJ; Levin RA; King AG
Br J Cancer; 2009 Nov; 101(10):1717-23. PubMed ID: 19844230
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic advances in women's cancers.
Carroll AR; Coleman RL; Sood AK
Front Biosci (Schol Ed); 2011 Jan; 3(1):82-97. PubMed ID: 21196359
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Rini BI
Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy in advanced non-small-cell lung cancer.
Gettinger S
Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
[TBL] [Abstract][Full Text] [Related]
8. The role of antiangiogenesis therapy: bevacizumab and beyond.
Cortés-Funes H
Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
[TBL] [Abstract][Full Text] [Related]
9. [Novelties in the treatment for advanced renal-cell cancer].
Maráz A
Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenic therapy: concept to clinic.
Young RJ; Reed MW
Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
[TBL] [Abstract][Full Text] [Related]
12. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
[TBL] [Abstract][Full Text] [Related]
13. Targeting angiogenesis in esophagogastric adenocarcinoma.
Okines AF; Reynolds AR; Cunningham D
Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy for breast cancer.
Nielsen DL; Andersson M; Andersen JL; Kamby C
Breast Cancer Res; 2010; 12(5):209. PubMed ID: 21067536
[TBL] [Abstract][Full Text] [Related]
15. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
Giles FJ
Oncologist; 2001; 6 Suppl 5():32-9. PubMed ID: 11700390
[TBL] [Abstract][Full Text] [Related]
16. In pursuit of new anti-angiogenic therapies for cancer treatment.
Cai J; Han S; Qing R; Liao D; Law B; Boulton ME
Front Biosci (Landmark Ed); 2011 Jan; 16(3):803-14. PubMed ID: 21196204
[TBL] [Abstract][Full Text] [Related]
17. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis as a therapeutic target in urothelial carcinoma.
Pinto A; Redondo A; Zamora P; Castelo B; Espinosa E
Anticancer Drugs; 2010 Nov; 21(10):890-6. PubMed ID: 20729712
[TBL] [Abstract][Full Text] [Related]
19. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Hagymási K; Tulassay Z
Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
[TBL] [Abstract][Full Text] [Related]
20. A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs.
Pauty J; Usuba R; Cheng IG; Hespel L; Takahashi H; Kato K; Kobayashi M; Nakajima H; Lee E; Yger F; Soncin F; Matsunaga YT
EBioMedicine; 2018 Jan; 27():225-236. PubMed ID: 29289530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
